Keywords: ImmuNext, Janssen Biotech, Johnson & Johnson, Cancer drug discovery

ImmuNext partners with Janssen in up to $150 million cancer discover deal

Article | 06 September 2012

Print This

Closely-held USA-based ImmuNext has entered into an agreement with Janssen Biotech, a unit of US health care giant Johnson & ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in